Import from "@/components/mdx"

Duavee Bone Health and Density Impact: What Women Need to Know

What Duavee Is and Why Bone Matters After Menopause

Duavee belongs to a class called tissue-selective estrogen complexes (TSECs). It pairs conjugated estrogens (CE), which provide the estrogenic signal that bone needs, with bazedoxifene (BZA), a selective estrogen receptor modulator (SERM) that acts as an estrogen antagonist in breast and uterine tissue while allowing estrogen-agonist activity in bone and the central nervous system.

Bone loss accelerates sharply around the menopause transition. In the two to three years surrounding the final menstrual period, women can lose 2 to 3 percent of bone mineral density (BMD) per year, a rate roughly three times faster than age-matched men losing bone over the same decade. By the time a woman reaches her mid-60s, cumulative losses can exceed 20 percent of peak bone mass, explaining why one in two women over 50 will experience an osteoporosis-related fracture during her lifetime, compared with one in five men.

Estrogen is the primary governor of bone turnover in women. It suppresses osteoclast activity (bone resorption) while supporting osteoblast function (bone formation). When estrogen drops at menopause, that brake on resorption releases, and bone is lost faster than it is made. Duavee restores enough estrogenic signaling at bone to meaningfully slow this process, without stimulating endometrial tissue the way unopposed estrogen would.

The Problem Duavee Solves

Standard estrogen-progestogen hormone therapy (EPT) prevents bone loss effectively, but many women experience progestogen-related side effects including mood changes, bloating, and irregular bleeding, especially in the perimenopause-to-early-postmenopause window. Progestogen-free options historically meant accepting endometrial risk with unopposed estrogen.

BZA solves this by acting as the endometrial protector. Women with a hysterectomy can use estrogen alone and skip this equation entirely. For everyone else with an intact uterus, CE/BZA offers a progestogen-free path to both symptom relief and bone protection.

The SMART Trials: What the Clinical Evidence Actually Shows

The Selective estrogens, Menopause, And Response to Therapy (SMART) program is a series of five phase III randomized controlled trials designed to evaluate multiple doses of CE combined with BZA across different endpoints in postmenopausal women. The key bone-health findings came from SMART-1, SMART-2, and SMART-5.

SMART-1: Two-Year BMD Results

SMART-1 was the largest trial in the program, enrolling 3,397 postmenopausal women aged 40 to 75 with an intact uterus. Participants were randomized to one of several CE/BZA dose combinations, CE alone, BZA alone, or placebo and followed for two years.

At the lumbar spine, women taking CE 0.45 mg/BZA 20 mg gained 1.51 percent BMD versus a loss of 1.37 percent in the placebo group, a net difference of approximately 2.9 percentage points. At the total hip, the CE 0.45 mg/BZA 20 mg arm showed a 0.35 percent gain versus a 1.28 percent loss in placebo, for a net difference of roughly 1.6 percentage points. These differences were statistically significant (p < 0.001 for both sites).

The CE 0.625 mg/BZA 20 mg combination produced slightly larger BMD gains at the spine (+1.95% versus placebo), but this higher dose was not the one chosen for FDA approval given the benefit-risk profile across all SMART endpoints.

SMART-5: Confirming Bone Findings in a Second Cohort

SMART-5 enrolled 1,843 postmenopausal women and ran for one year with a primary focus on endometrial safety, but BMD was also measured. Results confirmed the SMART-1 bone findings: CE 0.45 mg/BZA 20 mg produced a statistically significant increase in lumbar spine BMD compared with placebo at 12 months, consistent in magnitude with the two-year data.

Bone Turnover Markers: The Mechanism in Numbers

BMD changes measured by DXA are the clinical standard, but bone turnover markers give a more granular picture of what the drug is actually doing biochemically. In SMART-1, CE/BZA significantly reduced serum C-terminal telopeptide (CTX), a resorption marker, and procollagen type I N-terminal propeptide (P1NP), a formation marker, compared with placebo. The net effect was a reduction in the high-turnover state characteristic of early postmenopause. BZA alone also reduced turnover markers, which is expected for a SERM, but the combination produced greater suppression of resorption than BZA alone, reflecting the additive estrogenic input from CE.

How Duavee Compares With Raloxifene and Standard EPT

Raloxifene (Evista) is the other SERM used for osteoporosis prevention in postmenopausal women, but it does not treat hot flashes and may worsen them in early postmenopause. CE/BZA provides BMD preservation comparable to raloxifene at the spine while simultaneously controlling vasomotor symptoms, which is clinically significant because many women discontinue bone-protective therapy when it does not address their most bothersome symptoms.

Head-to-head data against raloxifene were not generated in the SMART program, so direct comparisons rely on network meta-analyses rather than randomized trials. Compared with standard EPT (CE 0.625 mg/medroxyprogesterone acetate 2.5 mg), CE/BZA produces somewhat smaller BMD gains, though the difference is modest in clinical terms and may be offset by improved tolerability in women who cannot tolerate progestogens.

Sex-Specific Physiology: Why Women's Bone Responds Differently

Estrogen Receptor Distribution in Female Bone

Female bone has a higher density of estrogen receptor-alpha (ER-alpha) than male bone, which is why estrogen loss at menopause triggers such a disproportionate bone-resorption response. BZA, as a SERM, binds the same receptor but produces a mixed agonist-antagonist signal depending on the tissue. In bone, BZA behaves as a partial agonist, and the addition of CE tips the balance further toward full agonist activity. This combination is more effective for bone than BZA alone precisely because of this receptor-level interaction.

The Perimenopausal Timing Window

The period of highest bone turnover and greatest opportunity for intervention is the two to four years immediately surrounding the final menstrual period. CE/BZA is approved for postmenopausal women only. The SMART trials enrolled women who were postmenopausal (12 months or more without a period), typically aged 40 to 75, with a mean age around 55. There are no published RCT data on CE/BZA in perimenopausal women, and the label does not support use in that stage.

Women who are in the late perimenopause and approaching this high-loss window should discuss timing of intervention with their clinician. Starting bone-protective therapy early in postmenopause captures the window of highest turnover and may yield the greatest long-term benefit.

PCOS, Premature Ovarian Insufficiency, and Earlier Bone Risk

Women with premature ovarian insufficiency (POI) experience estrogen deficiency years or decades earlier than the typical menopausal transition, meaning their lifetime exposure to bone-depleting estrogen withdrawal is far longer. CE/BZA is not approved for POI or premenopausal bone protection; these women typically require higher-dose estrogen therapy than the CE 0.45 mg component provides. Women with PCOS who have prolonged anovulation may also have irregular estrogen exposure during reproductive years that subtly affects peak bone mass, though the evidence in this area is limited and largely observational.

A useful clinical framework for matching bone therapy to life stage: women in reproductive years with bone risk (e.g., POI, eating disorders, amenorrhea) need hormone replacement at physiological premenopausal levels; women in early postmenopause with both vasomotor symptoms and bone risk are the ideal candidates for CE/BZA; women in late postmenopause who are asymptomatic and fracture-risk-positive may be better served by bisphosphonates or denosumab, which have anti-fracture efficacy data (CE/BZA has BMD data but not a completed fracture-reduction trial).

Pregnancy, Lactation, and Contraception: Required Reading

Duavee is contraindicated in women who are pregnant or may become pregnant.

CE/BZA is approved exclusively for postmenopausal use. Bazedoxifene carries a category X designation under the older FDA pregnancy category system. Estrogen-SERM combinations have not been studied in human pregnancy, and animal reproductive toxicology studies with bazedoxifene showed embryo-fetal harm at doses relevant to human exposure.

Key Points for Reproductive-Age Women Seeking Bone Protection

Because the drug is marketed for postmenopause, most prescribers will not encounter a reproductive-age woman requesting CE/BZA for bone health. However, the following points apply:

• Any woman of reproductive potential who is prescribed CE/BZA off-label (which is outside approved indications) would need highly effective, non-estrogen-sensitive contraception.
• Bazedoxifene itself is structurally related to SERMs that have been associated with fetal harm.
• The FDA label states explicitly: do not use in women with known or suspected pregnancy.

Lactation

CE/BZA is not indicated in premenopausal or postpartum women and has not been studied in lactating women. Conjugated estrogens are known to reduce milk production; this drug should not be used during breastfeeding.

Contraception Note for Perimenopausal Women

Women in late perimenopause can still ovulate unpredictably. CE/BZA is not a contraceptive and does not protect against pregnancy. A woman in late perimenopause considering CE/BZA would need to confirm postmenopausal status (FSH greater than 30 IU/L on two measurements at least six weeks apart, in the context of 12 months of amenorrhea) before beginning this therapy.

Who This Drug Is Right For (and Who It Is Not)

Best Candidates

Women most likely to benefit from CE/BZA for bone health meet several criteria:

• Postmenopausal with an intact uterus
• Have moderate-to-severe vasomotor symptoms that are also a treatment target (treating two problems with one drug)
• Have osteopenia (T-score between -1.0 and -2.5) at the spine or hip, or multiple risk factors for rapid bone loss
• Cannot tolerate or prefer to avoid progestogens because of side effects or personal preference
• Are within 10 years of menopause onset, where the bone-protective benefit relative to systemic risk is most favorable, as described by The Menopause Society's 2023 position statement on hormone therapy

Who Should Not Use Duavee

CE/BZA is not appropriate for:

• Women who have had a hysterectomy (they can use estrogen alone without a SERM/progestogen)
• Women with a history or active risk of estrogen-sensitive breast cancer or endometrial cancer
• Women with unexplained abnormal vaginal bleeding
• Women with active venous thromboembolism (VTE) or a high personal risk of VTE; bazedoxifene carries a VTE signal similar to other SERMs, and estrogen adds to this risk; the SMART-1 trial reported a VTE rate of 0.5 percent in the CE/BZA arm versus 0.2 percent in placebo, though absolute numbers were small
• Women with hepatic impairment; both CE and BZA are hepatically metabolized
• Women who are pregnant or breastfeeding

Osteoporosis vs. Osteoporosis Prevention: An Important Distinction

CE/BZA is FDA-approved for prevention of postmenopausal osteoporosis, not for treatment of established osteoporosis (T-score < -2.5 with or without fragility fracture). Women who already have osteoporosis by DXA criteria or who have had a fragility fracture should discuss bisphosphonates, denosumab, or anabolic agents (teriparatide, abaloparatide, romosozumab) with their clinician. CE/BZA may still play a role in symptom management for these women, but it should not be the sole bone-active agent when fracture risk is high.

Endometrial Safety: Why the Bone Benefit Doesn't Come at Uterine Cost

One of the most important clinical questions with any estrogen-containing regimen for a woman with a uterus is endometrial safety. The SMART-5 trial had endometrial safety as its primary endpoint and demonstrated endometrial hyperplasia rates below 1 percent at 12 months with CE 0.45 mg/BZA 20 mg, which met the prespecified non-inferiority criterion against placebo (the regulatory threshold is <1% hyperplasia rate). Endometrial thickness by transvaginal ultrasound did not increase significantly compared with placebo.

This safety profile directly supports the mechanism: BZA occupies uterine estrogen receptors as an antagonist, blocking the proliferative effect that CE would otherwise exert on the endometrium. The result is endometrial quiescence while bone (and the hypothalamus) receive estrogenic stimulation.

Clinically, this translates to reduced rates of uterine bleeding versus cyclic progestogen regimens. In SMART-5, amenorrhea rates with CE/BZA were greater than 80 percent at 12 months, which many postmenopausal women strongly prefer.

Breast Tissue: What the Data Show

Breast safety in hormone therapy is a topic of significant concern for most women, and the TSEC approach was partly designed to reduce mammographic breast density, a surrogate marker associated with breast cancer risk and imaging difficulty.

In SMART-3, a dedicated breast-safety substudy, CE/BZA 0.45/20 mg did not increase mammographic breast density compared with placebo at 12 months, in contrast to CE/MPA (medroxyprogesterone acetate), which significantly increases density. BZA's antagonist activity in breast tissue is the proposed mechanism. Long-term breast cancer incidence data from CE/BZA are not yet available from completed trials; the SMART program was two years in duration and was not powered for cancer endpoints. This evidence gap is real and should be communicated to patients.

The FDA label for Duavee carries the same class-wide boxed warning for breast cancer risk that all estrogen-containing products carry, because long-term cancer outcome data specific to CE/BZA remain incomplete. Women with a strong family history of breast cancer or prior biopsy-confirmed atypical hyperplasia should have this conversation carefully with their clinician before starting.

Dosing, Administration, and Drug Interactions Relevant to Women

CE/BZA is available as a single fixed-dose tablet: CE 0.45 mg and BZA 20 mg. The dose is one tablet once daily, taken orally with or without food.

Calcium and Vitamin D Co-administration

The SMART trials required participants to take supplemental calcium (600 mg/day) and vitamin D (200 IU/day), which is below what most current guidelines recommend. The Menopause Society's 2023 guidance recommends 1,200 mg/day of calcium (from food and supplement combined) and 1,500 to 2,000 IU/day of vitamin D for postmenopausal women at risk for bone loss. Women taking CE/BZA should meet these higher targets, not just the trial minimum.

Drug Interactions

• Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) may reduce BZA and CE plasma levels, potentially diminishing both bone and endometrial protection.
• Cholestyramine and other bile acid sequestrants reduce CE absorption; separate administration by at least four hours.
• No clinically significant interaction has been identified between CE/BZA and most antihypertensives or statins, which are commonly co-administered in the postmenopausal population.

Duration of Use

The FDA-approved duration for bone prevention with CE/BZA has not been formally capped. General hormone therapy guidance from The Menopause Society and ACOG Practice Bulletin No. 141 supports individualized duration rather than a blanket five-year limit, with annual re-evaluation of benefits and risks. Bone protection presumably continues as long as therapy continues; the SMART program did not include post-discontinuation follow-up adequate to determine durability of BMD gains after stopping.

Monitoring Bone Health While on Duavee

A woman starting CE/BZA for bone prevention should have a baseline DXA scan. Repeat DXA at two years is reasonable to document response. If BMD is stable or improving, continuation and two- to three-year DXA intervals are appropriate. If BMD continues to decline significantly on CE/BZA, re-evaluation of adherence, calcium/vitamin D adequacy, and secondary causes of bone loss (thyroid dysfunction, celiac disease, vitamin D malabsorption) should precede switching to a bisphosphonate.

Secondary causes of bone loss deserve particular attention in women. Postpartum thyroiditis occurs in approximately 5 to 10 percent of women in the first year after delivery, and untreated hypothyroidism or excess levothyroxine suppression therapy can both affect bone. Women on thyroid therapy who are also starting CE/BZA should have TSH checked to confirm thyroid status is optimized.

Fracture risk assessment using FRAX (Fracture Risk Assessment Tool) at baseline helps contextualize the DXA finding. Women with a 10-year major osteoporotic fracture risk above 20 percent or hip fracture risk above 3 percent by FRAX generally meet thresholds where pharmacological therapy is warranted; if they also have vasomotor symptoms, CE/BZA is a reasonable first-line option rather than defaulting immediately to bisphosphonates.

A Clinical Note on Evidence Gaps for Women

Women have been under-represented in bone drug trials, and CE/BZA is a partial exception: the SMART program enrolled exclusively women, which is appropriate given the drug's indication. The average SMART participant was a healthy, non-obese postmenopausal woman in her mid-50s. Data in women over 70, women with obesity (BMI >35), women with prior fracture, and women with multiple comorbidities are sparse. Extrapolation of the SMART BMD findings to these subgroups should be done cautiously.

The absence of a powered fracture-reduction trial for CE/BZA is the most significant evidence gap. Every bisphosphonate approved for osteoporosis treatment has demonstrated fracture reduction in key RCTs (e.g., the FIT trial for alendronate demonstrated a 47 percent reduction in hip fracture at three years). CE/BZA does not have an equivalent trial. BMD improvement is a validated surrogate, but it is not fracture reduction. This distinction matters when counseling a woman at high fracture risk.